Ruiyan Ma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ruiyan Ma has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Yingbin Xiao
Department of Cardiovascular Surgery, the Second Affiliated Hospital, Army Medical University, Chongqing, China
5 shared publications - Chenyang Duan
Department of Critical Care Medicine, The Second Affiliated Hospital of Chongqing Medical University , Chongqing 400010
4 shared publications - He Huang
Department of Anesthesiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
3 shared publications Ruixue Liu
Department of Critical Care Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, P.R. China
3 shared publicationsZhezhe Cao
Department of Cardiovascular Surgery, Xinqiao Hospital, Army Medical University, Chongqing, P.R. China
3 shared publicationsChunshui Liang
Department of Cardiovascular Surgery, Xinqiao Hospital, The Army Medical University
2 shared publications
Latest Publications
- Open Access
- 3 September 2026
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 13, 1865765
Clinical outcomes of external fenestration TEVAR in Stanford type B aortic dissection involving the left subclavian artery: a retrospective study
Objective: This study assessed the clinical efficacy and hemodynamic effects of external fenestration thoracic endovascular aortic repair (TEVAR) in patients with type B aortic dissection (TBAD) involving the left subclavian artery (LSA). Methods: A retrospective analysis of 110 patients who underwent this procedure between 2020 and 2024 was conducted, evaluating procedural success, complications, and follow-up outcomes. Hemodynamic changes were analyzed in 1 patient using computational fluid dynamics (CFD) based on pre- and postoperative CT angiography (CTA). Results: Technical success was achieved in all cases. Complications included 3 cases of type I endoleak (2.7%), 1 type II endoleak (0.9%), 3 type IV endoleak (2.7%), 1 LSA stenosis (0.9%), and 2 deaths (1.8%). At a 5.7-month follow-up, 92.7% of patients showed complete false lumen thrombosis. There were occurrences of type I endoleak (2.7%), type II endoleak (1.8%), type IV endoleak (2.7%), LSA occlusion (2.7%), and LSA stenosis (2.7%). CFD analysis in the representative case demonstrated restoration of physiological flow patterns, including normalized streamlines in the LSA and stabilized wall shear stress in the stented segment. Conclusion: External fenestration TEVAR demonstrates favorable clinical outcomes and hemodynamic stability in TBAD involving the LSA, effectively promoting false lumen thrombosis and aortic remodeling while preserving LSA perfusion. Our findings suggest that complete entry coverage with an adequate proximal landing zone (≥15 mm when anatomically feasible) may be important for achieving false lumen depressurization, although this observation requires further validation. Further prospective studies are warranted to validate these findings.
- 3 September 2026
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 13, 1865765
Open AccessClinical outcomes of external fenestration TEVAR in Stanford type B aortic dissection involving the left subclavian artery: a retrospective study
Objective: This study assessed the clinical efficacy and hemodynamic effects of external fenestration thoracic endovascular aortic repair (TEVAR) in patients with type B aortic dissection (TBAD) involving the left subclavian artery (LSA). Methods: A retrospective analysis of 110 patients who underwent this procedure between 2020 and 2024 was conducted, evaluating procedural success, complications, and follow-up outcomes. Hemodynamic changes were analyzed in 1 patient using computational fluid dynamics (CFD) based on pre- and postoperative CT angiography (CTA). Results: Technical success was achieved in all cases. Complications included 3 cases of type I endoleak (2.7%), 1 type II endoleak (0.9%), 3 type IV endoleak (2.7%), 1 LSA stenosis (0.9%), and 2 deaths (1.8%). At a 5.7-month follow-up, 92.7% of patients showed complete false lumen thrombosis. There were occurrences of type I endoleak (2.7%), type II endoleak (1.8%), type IV endoleak (2.7%), LSA occlusion (2.7%), and LSA stenosis (2.7%). CFD analysis in the representative case demonstrated restoration of physiological flow patterns, including normalized streamlines in the LSA and stabilized wall shear stress in the stented segment. Conclusion: External fenestration TEVAR demonstrates favorable clinical outcomes and hemodynamic stability in TBAD involving the LSA, effectively promoting false lumen thrombosis and aortic remodeling while preserving LSA perfusion. Our findings suggest that complete entry coverage with an adequate proximal landing zone (≥15 mm when anatomically feasible) may be important for achieving false lumen depressurization, although this observation requires further validation. Further prospective studies are warranted to validate these findings.
- Open Access
- 9 March 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
SIRT3 deficiency impairs mitochondrial bioenergetics via hyperacetylation of TCA cycle enzymes in chronic heart failure
Mitochondrial dysfunction is a hallmark of heart failure (HF), but its upstream regulatory pathways remain incompletely understood. Sirtuin 3 (SIRT3), a mi
- 9 March 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Open AccessSIRT3 deficiency impairs mitochondrial bioenergetics via hyperacetylation of TCA cycle enzymes in chronic heart failure
Mitochondrial dysfunction is a hallmark of heart failure (HF), but its upstream regulatory pathways remain incompletely understood. Sirtuin 3 (SIRT3), a mi
- Open Access
- 27 January 2026
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (4) , 10104-10116
Timely surgical intervention and risk stratification in patients with Ebstein anomaly: a 20-year retrospective cohort study
Background: The optimal timing and choice of surgery for Ebstein anomaly (EA), a complex congenital heart defect, remain challenging due to the heterogeneity and lack of robust long-term data on EA. In this study, we aimed to evaluate the long-term outcomes of surgical management in patients with EA, identify the prognostic risk factors, and develop a predictive model. Materials and Methods: We conducted a retrospective analysis of data from 332 patients with EA who were treated at a tertiary center between January 2000 and December 2021. Among them, 269 underwent surgery: tricuspid valve repairs, 150; replacements, 77; and isolated bidirectional Glenn procedures, 42. Additionally, 70 patients received a concomitant Glenn shunt during valve surgery, resulting in a total of 112 Glenn procedures. The median follow-up was 10.12 years. The primary outcomes were freedom from reoperation and medical interventions. A predictive nomogram was developed using least absolute shrinkage and selection operator regression and internally validated. Results: The early surgical mortality rate was 2.60%. Postoperative complications occurred in 15.24% of the patients, with renal failure (4.83%) and arrhythmias (2.23%) being the most common. During a median follow-up of 10.12 years, the freedom from operation rates were 97.95, 92.48, 87.04, and 83.22% at 5, 10, 15, and 20 years, respectively. However, freedom from medical intervention showed a progressive decline (94.34% at 5 years vs. 62.31% at 20). Multivariable Cox regression analysis identified preoperative hepatic congestion [hazard ratio (HR) = 3.042], Wolff–Parkinson–White (WPW) syndrome (HR = 3.463), and elevated alanine aminotransferase (ALT) level (HR = 1.023) as independent risk factors for surgery. The concomitant bidirectional Glenn procedure was associated with a significantly reduced risk of both reoperation (HR = 0.160) and medical intervention (HR = 0.259). Patients requiring interventions showed significantly worse physical and emotional quality-of-life scores than did those who were event-free ( P < 0.05). Conclusion: Timely surgical intervention guided by preoperative risk stratification optimizes the long-term outcomes of EA. The proposed nomogram was a practical tool for individualized risk assessment, supporting clinical decision making in patients with this complex condition.
- 27 January 2026
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (4) , 10104-10116
Open AccessTimely surgical intervention and risk stratification in patients with Ebstein anomaly: a 20-year retrospective cohort study
Background: The optimal timing and choice of surgery for Ebstein anomaly (EA), a complex congenital heart defect, remain challenging due to the heterogeneity and lack of robust long-term data on EA. In this study, we aimed to evaluate the long-term outcomes of surgical management in patients with EA, identify the prognostic risk factors, and develop a predictive model. Materials and Methods: We conducted a retrospective analysis of data from 332 patients with EA who were treated at a tertiary center between January 2000 and December 2021. Among them, 269 underwent surgery: tricuspid valve repairs, 150; replacements, 77; and isolated bidirectional Glenn procedures, 42. Additionally, 70 patients received a concomitant Glenn shunt during valve surgery, resulting in a total of 112 Glenn procedures. The median follow-up was 10.12 years. The primary outcomes were freedom from reoperation and medical interventions. A predictive nomogram was developed using least absolute shrinkage and selection operator regression and internally validated. Results: The early surgical mortality rate was 2.60%. Postoperative complications occurred in 15.24% of the patients, with renal failure (4.83%) and arrhythmias (2.23%) being the most common. During a median follow-up of 10.12 years, the freedom from operation rates were 97.95, 92.48, 87.04, and 83.22% at 5, 10, 15, and 20 years, respectively. However, freedom from medical intervention showed a progressive decline (94.34% at 5 years vs. 62.31% at 20). Multivariable Cox regression analysis identified preoperative hepatic congestion [hazard ratio (HR) = 3.042], Wolff–Parkinson–White (WPW) syndrome (HR = 3.463), and elevated alanine aminotransferase (ALT) level (HR = 1.023) as independent risk factors for surgery. The concomitant bidirectional Glenn procedure was associated with a significantly reduced risk of both reoperation (HR = 0.160) and medical intervention (HR = 0.259). Patients requiring interventions showed significantly worse physical and emotional quality-of-life scores than did those who were event-free ( P < 0.05). Conclusion: Timely surgical intervention guided by preoperative risk stratification optimizes the long-term outcomes of EA. The proposed nomogram was a practical tool for individualized risk assessment, supporting clinical decision making in patients with this complex condition.
- Open Access
- 1 January 2026
- Published by Wiley in Journal of Interventional Cardiology
- Vol. 2026 (1)
Transapical TAVR Using a Modified J‐Valve for Pure Aortic Regurgitation in Large Aortic Annuli: A Single‐Center Experience
Objective: To evaluate the safety and efficacy of transapical implantation of a modified J‐Valve in patients with pure aortic regurgitation (AR) and large aortic annuli (> 29 mm). Methods: This retrospective single‐center study included 10 high surgical risk patients (STS‐PROM: 8.3%–13.1%) with pure AR and annular diameters > 29 mm who underwent transapical implantation of a J‐Valve prosthesis externally reinforced with a Dacron patch between December 2018 and September 2024. Endpoints were defined according to the Valve Academic Research Consortium‐3 (VARC‐3) criteria. Procedural outcomes, echocardiographic data, and 30‐day complications were analyzed. Results: All procedures were technically successful, with no intraoperative mortality, stroke, or vascular complications. Postoperatively, one patient required permanent pacemaker implantation. Perivalvular leakage (PVL) was observed in five patients (four trace/mild, one moderate) immediately postprocedure. At a median follow‐up of 6.5 months, PVL was present in three patients (two trace, one moderate). Significant reductions in left ventricular dimensions and stable hemodynamic parameters were noted. No subclinical leaflet thrombosis occurred. Conclusions: Transapical implantation of a modified J‐Valve with an external Dacron skirt appears technically feasible with acceptable short‐term safety for highly selected high‐risk patients with pure AR and large annuli (> 29 mm). However, the limited sample size precludes broad applicability, and longer term follow‐up is required.
- 1 January 2026
- Published by Wiley in Journal of Interventional Cardiology
- Vol. 2026 (1)
Open AccessTransapical TAVR Using a Modified J‐Valve for Pure Aortic Regurgitation in Large Aortic Annuli: A Single‐Center Experience
Objective: To evaluate the safety and efficacy of transapical implantation of a modified J‐Valve in patients with pure aortic regurgitation (AR) and large aortic annuli (> 29 mm). Methods: This retrospective single‐center study included 10 high surgical risk patients (STS‐PROM: 8.3%–13.1%) with pure AR and annular diameters > 29 mm who underwent transapical implantation of a J‐Valve prosthesis externally reinforced with a Dacron patch between December 2018 and September 2024. Endpoints were defined according to the Valve Academic Research Consortium‐3 (VARC‐3) criteria. Procedural outcomes, echocardiographic data, and 30‐day complications were analyzed. Results: All procedures were technically successful, with no intraoperative mortality, stroke, or vascular complications. Postoperatively, one patient required permanent pacemaker implantation. Perivalvular leakage (PVL) was observed in five patients (four trace/mild, one moderate) immediately postprocedure. At a median follow‐up of 6.5 months, PVL was present in three patients (two trace, one moderate). Significant reductions in left ventricular dimensions and stable hemodynamic parameters were noted. No subclinical leaflet thrombosis occurred. Conclusions: Transapical implantation of a modified J‐Valve with an external Dacron skirt appears technically feasible with acceptable short‐term safety for highly selected high‐risk patients with pure AR and large annuli (> 29 mm). However, the limited sample size precludes broad applicability, and longer term follow‐up is required.
- Open Access
- 14 November 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (2) , 3238-3251
Global, regional, and national burden of non-rheumatic calcific aortic valve disease, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
Background: Non-rheumatic calcific aortic valve disease (NRCAVD) has emerged as a critical global health challenge, intensified by aging populations and persistent sociodemographic disparities. Existing studies inadequately address its specific disease burden and associated health inequities. This study aims to comprehensively evaluate the global, regional, and national burden of NRCAVD from 1990 to 2021 to inform equitable public health policies and resource allocation strategies. Materials and Methods: Utilizing the Global Burden of Disease (GBD) 2021 dataset, we quantified NRCAVD burden through age-standardized incidence rates (ASIR), mortality (ASDR), disability-adjusted life years (DALYs), and sociodemographic index (SDI). Key drivers of burden trends were identified via age-sex decomposition, age-period-cohort (APC) modeling. Health inequalities and TAVR penetration were assessed through disparity metrics, while Bayesian age-period-cohort (BAPC) models projected future trajectories to 2041. Results: Between 1990 and 2021, global NRCAVD burden increased significantly, with males and populations in high-SDI regions experiencing disproportionately higher burdens. While women showed lower disease incidence, they faced higher mortality rates. Health disparities worsened primarily due to aging and population growth. Higher penetration of TAVR is associated with a decrease in ASDR of NRCAVD, which was observed in multinational registries. Incidence peaked at ages 75–79, whereas mortality and DALYs were highest at 85–89 years. Projections indicate declining age-standardized rates (ASIR: -2.88%, ASDR: -0.69%, DALYs: -7.54% by 2041), though reductions lagged in males compared to females. Conclusion: Global NRCAVD burden remains unequal, particularly in high-SDI regions where mortality rates are disproportionately high. Addressing widening inequalities requires sex-specific interventions for aging populations, expanded access to cost-effective valvular therapies, and strengthened health systems in underserved regions. Multinational collaboration to standardize NRCAVD surveillance and share best practices in lifecycle management is imperative to achieve health equity in an aging world.
- 14 November 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (2) , 3238-3251
Open AccessGlobal, regional, and national burden of non-rheumatic calcific aortic valve disease, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
Background: Non-rheumatic calcific aortic valve disease (NRCAVD) has emerged as a critical global health challenge, intensified by aging populations and persistent sociodemographic disparities. Existing studies inadequately address its specific disease burden and associated health inequities. This study aims to comprehensively evaluate the global, regional, and national burden of NRCAVD from 1990 to 2021 to inform equitable public health policies and resource allocation strategies. Materials and Methods: Utilizing the Global Burden of Disease (GBD) 2021 dataset, we quantified NRCAVD burden through age-standardized incidence rates (ASIR), mortality (ASDR), disability-adjusted life years (DALYs), and sociodemographic index (SDI). Key drivers of burden trends were identified via age-sex decomposition, age-period-cohort (APC) modeling. Health inequalities and TAVR penetration were assessed through disparity metrics, while Bayesian age-period-cohort (BAPC) models projected future trajectories to 2041. Results: Between 1990 and 2021, global NRCAVD burden increased significantly, with males and populations in high-SDI regions experiencing disproportionately higher burdens. While women showed lower disease incidence, they faced higher mortality rates. Health disparities worsened primarily due to aging and population growth. Higher penetration of TAVR is associated with a decrease in ASDR of NRCAVD, which was observed in multinational registries. Incidence peaked at ages 75–79, whereas mortality and DALYs were highest at 85–89 years. Projections indicate declining age-standardized rates (ASIR: -2.88%, ASDR: -0.69%, DALYs: -7.54% by 2041), though reductions lagged in males compared to females. Conclusion: Global NRCAVD burden remains unequal, particularly in high-SDI regions where mortality rates are disproportionately high. Addressing widening inequalities requires sex-specific interventions for aging populations, expanded access to cost-effective valvular therapies, and strengthened health systems in underserved regions. Multinational collaboration to standardize NRCAVD surveillance and share best practices in lifecycle management is imperative to achieve health equity in an aging world.
- Open Access
- 28 April 2025
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 12, 1530548
Successful treatment of massive biventricular thrombi associated with myocarditis: a case report
Background: Massive biventricular thrombi associated with myocarditis are rare and pose significant management challenges.Case presentation: A 24-year-old male from a plateau region presented with dyspnea, chest pain, and cerebral infarction/hemorrhage. Imaging revealed giant biventricular thrombi (left: 81 × 62 × 59 mm; right: 59 × 16 mm) and LVEF of 25%.Management: Multidisciplinary therapy included anticoagulation and GDMT.Outcomes: Complete thrombus resolution occurred by 10 weeks, with improved cardiac function (LVEF 48%) and no recurrent embolism.Conclusion: Drug therapy may be effective for massive biventricular thrombi in myocarditis.
- 28 April 2025
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 12, 1530548
Open AccessSuccessful treatment of massive biventricular thrombi associated with myocarditis: a case report
Background: Massive biventricular thrombi associated with myocarditis are rare and pose significant management challenges.Case presentation: A 24-year-old male from a plateau region presented with dyspnea, chest pain, and cerebral infarction/hemorrhage. Imaging revealed giant biventricular thrombi (left: 81 × 62 × 59 mm; right: 59 × 16 mm) and LVEF of 25%.Management: Multidisciplinary therapy included anticoagulation and GDMT.Outcomes: Complete thrombus resolution occurred by 10 weeks, with improved cardiac function (LVEF 48%) and no recurrent embolism.Conclusion: Drug therapy may be effective for massive biventricular thrombi in myocarditis.
- Open Access
- 13 October 2023
- Published by Elsevier in Military Medical Research
- Vol. 10 (1) , 1-27
Multifaceted functions of Drp1 in hypoxia/ischemia-induced mitochondrial quality imbalance: from regulatory mechanism to targeted therapeutic strategy
- 13 October 2023
- Published by Elsevier in Military Medical Research
- Vol. 10 (1) , 1-27
Open AccessMultifaceted functions of Drp1 in hypoxia/ischemia-induced mitochondrial quality imbalance: from regulatory mechanism to targeted therapeutic strategy
- RetractedOpen Access
- 30 September 2022
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2022 (1) , 7958542
[Retracted] Oxidative‐Damaged Mitochondria Activate GABARAPL1‐Induced NLRP3 Inflammasomes in an Autophagic‐Exosome Manner after Acute Myocardial Ischemia
Objective. This study is aimed at identifying the potential diagnostic markers for circulating endothelial cells (CECs) for acute myocardial ischemia (AMI) and exploring the regulatory mechanisms of the selected biomarker in mitochondrial oxidative damage and vascular inflammation in AMI pathology. Methods. Utilizing the Gene Expression Omnibus dataset GSE66360, we scanned for differentially expressed genes (DEGs) in 49 AMI patients and 50 healthy subjects. To discover possible biomarkers, LASSO regression and support vector machine recursive feature elimination examinations were conducted. Using the GSE60993 and GSE123342 datasets and AMI rat models, the expression levels and diagnostic accuracy of the biomarkers in AMI were thoroughly verified. CIBERSORT was employed to evaluate the compositional patterns of 22 distinct immunological cell percentages in AMI according to combined cohorts. The oxidative‐damaged mitochondria were detected by confocal microscopy observation of MitoTracker, ROS‐DCFH‐DA, and mCherry‐GFP‐LC3B. Results. In total, 122 genes were identified. The identified DEGs primarily contributed in arteriosclerosis, arteriosclerotic cardiovascular disorders, bacterial infectious disorder, coronary artery disease, and myocardial infarction. Nine features (NR4A2, GABARAPL1 (GEC1), CLEC4D, ITLN1, SNORD89, ZFP36, CH25H, CCR2, and EFEMP1) of the DEGs were shared by two algorithms, and GABARAPL1 (GEC1) was identified and verified as a diagnostic mitochondrial biomarker for AMI. Confocal results showed that there existed mitochondrial damage and oxidative stress in cardiac CMECs after AMI, and the blocked autophagy flux could be released by exosome burst in cardiac CMECs and blood CECs. Immune cell infiltration testing declared that elevated GEC1 expression in blood CECs was linked to the rise of monocytes and neutrophils. Functional tests revealed that high GEC1 expression in CMECs and CECs could activate the vascular inflammatory response by stimulating NLRP3 inflammasome production after AMI. Conclusion. Oxidative‐damaged mitochondria in cardiac CMECs activate GEC1‐mediated autophagosomes but block autophagy flux after AMI. The exfoliated cardiac CMECs evolve into abnormal blood CECs, and the undegraded GEC1 autophagosomes produce a large number of NLRP3 inflammasomes by exosome burst, stimulating the increase in monocytes and neutrophils and ultimately triggering vascular inflammation after AMI. Therefore, GEC1 in blood CECs is a highly specific diagnostic mitochondrial biomarker for AMI.
- 30 September 2022
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2022 (1) , 7958542
RetractedOpen Access[Retracted] Oxidative‐Damaged Mitochondria Activate GABARAPL1‐Induced NLRP3 Inflammasomes in an Autophagic‐Exosome Manner after Acute Myocardial Ischemia
Objective. This study is aimed at identifying the potential diagnostic markers for circulating endothelial cells (CECs) for acute myocardial ischemia (AMI) and exploring the regulatory mechanisms of the selected biomarker in mitochondrial oxidative damage and vascular inflammation in AMI pathology. Methods. Utilizing the Gene Expression Omnibus dataset GSE66360, we scanned for differentially expressed genes (DEGs) in 49 AMI patients and 50 healthy subjects. To discover possible biomarkers, LASSO regression and support vector machine recursive feature elimination examinations were conducted. Using the GSE60993 and GSE123342 datasets and AMI rat models, the expression levels and diagnostic accuracy of the biomarkers in AMI were thoroughly verified. CIBERSORT was employed to evaluate the compositional patterns of 22 distinct immunological cell percentages in AMI according to combined cohorts. The oxidative‐damaged mitochondria were detected by confocal microscopy observation of MitoTracker, ROS‐DCFH‐DA, and mCherry‐GFP‐LC3B. Results. In total, 122 genes were identified. The identified DEGs primarily contributed in arteriosclerosis, arteriosclerotic cardiovascular disorders, bacterial infectious disorder, coronary artery disease, and myocardial infarction. Nine features (NR4A2, GABARAPL1 (GEC1), CLEC4D, ITLN1, SNORD89, ZFP36, CH25H, CCR2, and EFEMP1) of the DEGs were shared by two algorithms, and GABARAPL1 (GEC1) was identified and verified as a diagnostic mitochondrial biomarker for AMI. Confocal results showed that there existed mitochondrial damage and oxidative stress in cardiac CMECs after AMI, and the blocked autophagy flux could be released by exosome burst in cardiac CMECs and blood CECs. Immune cell infiltration testing declared that elevated GEC1 expression in blood CECs was linked to the rise of monocytes and neutrophils. Functional tests revealed that high GEC1 expression in CMECs and CECs could activate the vascular inflammatory response by stimulating NLRP3 inflammasome production after AMI. Conclusion. Oxidative‐damaged mitochondria in cardiac CMECs activate GEC1‐mediated autophagosomes but block autophagy flux after AMI. The exfoliated cardiac CMECs evolve into abnormal blood CECs, and the undegraded GEC1 autophagosomes produce a large number of NLRP3 inflammasomes by exosome burst, stimulating the increase in monocytes and neutrophils and ultimately triggering vascular inflammation after AMI. Therefore, GEC1 in blood CECs is a highly specific diagnostic mitochondrial biomarker for AMI.
- RetractedOpen Access
- 24 September 2022
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2022 (1) , 3858871
[Retracted] Identification of MMP9 as a Novel Biomarker to Mitochondrial Metabolism Disorder and Oxidative Stress in Calcific Aortic Valve Stenosis
Calcific aortic valve stenosis (CAVS) is the most common heart valve disorder among humans. To date, no effective method has been identified to prevent this disease. Herein, we aimed to identify novel diagnostic and mitochondria‐related biomarkers of CAVS, based on two machine learning algorithms. We further explored their association with infiltrating immune cells and studied their potential function in CAVS. The GSE12644, GSE51472, and GSE83453 expression profiles were downloaded from the Gene Expression Omnibus (GEO) repository. The GSE12644 and GSE51472 datasets were integrated to identify differentially expressed genes (DEGs). GSE12644 contains 10 normal and 10 CAVS samples, whereas GSE51472 contains 5 normal and 10 CAVS samples. GO and KEGG assays of DEGs were conducted, and the correlation between matrix metalloproteinase 9 (MMP9) expression and immune cell infiltration was explored, using CIBERSORT. The LASSO regression model and SVM‐RFE analysis were used to identify diagnostic genes. The expression of MMP9 in CAVS and non‐CAVS samples was measured using RT‐PCR, western blotting and immunohistochemistry. A series of functional experiments were performed to explore the potential role of MMP9 in mitochondrial metabolism and oxidative stress during CAVS progression. Twenty‐two DEGs were identified, of which six genes (SCG2, PPBP, TREM1, CCL19, WIF1, and MMP9) were ultimately distinguished as diagnostic genes in CAVS. Of these, MMP9 was indicated as a mitochondria‐related gene, the expression and diagnostic value of which were further confirmed in the GSE83453 dataset. Correlation analysis revealed a positive correlation between MMP9 and infiltrating immune cells. In our cohort, MMP9 expression was distinctly increased in CAVS samples, and its inhibition attenuated the calcification of valve interstitial cells (VICs) by suppressing mitochondrial damage and oxidative stress. Taken together, our findings suggest MMP9 as a novel mitochondrial dysfunction biomarker and therapeutic target for CAVS.
- 24 September 2022
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2022 (1) , 3858871
RetractedOpen Access[Retracted] Identification of MMP9 as a Novel Biomarker to Mitochondrial Metabolism Disorder and Oxidative Stress in Calcific Aortic Valve Stenosis
Calcific aortic valve stenosis (CAVS) is the most common heart valve disorder among humans. To date, no effective method has been identified to prevent this disease. Herein, we aimed to identify novel diagnostic and mitochondria‐related biomarkers of CAVS, based on two machine learning algorithms. We further explored their association with infiltrating immune cells and studied their potential function in CAVS. The GSE12644, GSE51472, and GSE83453 expression profiles were downloaded from the Gene Expression Omnibus (GEO) repository. The GSE12644 and GSE51472 datasets were integrated to identify differentially expressed genes (DEGs). GSE12644 contains 10 normal and 10 CAVS samples, whereas GSE51472 contains 5 normal and 10 CAVS samples. GO and KEGG assays of DEGs were conducted, and the correlation between matrix metalloproteinase 9 (MMP9) expression and immune cell infiltration was explored, using CIBERSORT. The LASSO regression model and SVM‐RFE analysis were used to identify diagnostic genes. The expression of MMP9 in CAVS and non‐CAVS samples was measured using RT‐PCR, western blotting and immunohistochemistry. A series of functional experiments were performed to explore the potential role of MMP9 in mitochondrial metabolism and oxidative stress during CAVS progression. Twenty‐two DEGs were identified, of which six genes (SCG2, PPBP, TREM1, CCL19, WIF1, and MMP9) were ultimately distinguished as diagnostic genes in CAVS. Of these, MMP9 was indicated as a mitochondria‐related gene, the expression and diagnostic value of which were further confirmed in the GSE83453 dataset. Correlation analysis revealed a positive correlation between MMP9 and infiltrating immune cells. In our cohort, MMP9 expression was distinctly increased in CAVS samples, and its inhibition attenuated the calcification of valve interstitial cells (VICs) by suppressing mitochondrial damage and oxidative stress. Taken together, our findings suggest MMP9 as a novel mitochondrial dysfunction biomarker and therapeutic target for CAVS.
- Open Access
- 25 May 2021
- Published by Wiley in International Wound Journal
- Vol. 19 (2) , 253-261
A nomogram prediction model for sternal incision problems
Presently, the incidence and mortality rates of sternal incision problems (SIPs) after thoracotomy remain high, and no effective preventive measures are available. The data on 23 182 patients at Xinqiao Hospital, Army Medical University treated with median sternotomy from 1 August 2009 to 31 July 2019 were retrospectively reviewed. A prediction model of SIPs after median thoracotomy was established using R software and then validated using the bootstrap method. Next, the validity and accuracy of the model were tested and evaluated. In total, 15 426 cases met the requirements of the present study, among which 309 cases were diagnosed with SIPs, with an incidence rate of 2%. The body mass index (BMI), intensive care unit (ICU) time, diabetes mellitus, and revision for bleeding were identified as independent risk factors for postoperative SIPs. The nomogram model achieved good discrimination (73.9%) and accuracy (70.2%) in predicting the risk of SIPs after median thoracotomy. Receiver operating characteristic curve analysis showed that the area under curve of the model was 0.705 (95% confidence interval [CI]: 0.746‐0.803); the Hosmer‐Lemeshow test showed that χ2 = 6.987 and P = 0.538, and the fitting degree of the calibration curve was good. Additionally, the clinical decision curve showed that the net benefit of the model was greater than 0, and the clinical application value was high. The nomogram based on BMI, ICU time, diabetes mellitus, and revision for bleeding can predict the individualised risk of SIPs after median sternotomy, showing good discrimination and accuracy, and has high clinical application value. It also provides significant guidance for screening high‐risk populations and developing intervention strategies.
- 25 May 2021
- Published by Wiley in International Wound Journal
- Vol. 19 (2) , 253-261
Open AccessA nomogram prediction model for sternal incision problems
Presently, the incidence and mortality rates of sternal incision problems (SIPs) after thoracotomy remain high, and no effective preventive measures are available. The data on 23 182 patients at Xinqiao Hospital, Army Medical University treated with median sternotomy from 1 August 2009 to 31 July 2019 were retrospectively reviewed. A prediction model of SIPs after median thoracotomy was established using R software and then validated using the bootstrap method. Next, the validity and accuracy of the model were tested and evaluated. In total, 15 426 cases met the requirements of the present study, among which 309 cases were diagnosed with SIPs, with an incidence rate of 2%. The body mass index (BMI), intensive care unit (ICU) time, diabetes mellitus, and revision for bleeding were identified as independent risk factors for postoperative SIPs. The nomogram model achieved good discrimination (73.9%) and accuracy (70.2%) in predicting the risk of SIPs after median thoracotomy. Receiver operating characteristic curve analysis showed that the area under curve of the model was 0.705 (95% confidence interval [CI]: 0.746‐0.803); the Hosmer‐Lemeshow test showed that χ2 = 6.987 and P = 0.538, and the fitting degree of the calibration curve was good. Additionally, the clinical decision curve showed that the net benefit of the model was greater than 0, and the clinical application value was high. The nomogram based on BMI, ICU time, diabetes mellitus, and revision for bleeding can predict the individualised risk of SIPs after median sternotomy, showing good discrimination and accuracy, and has high clinical application value. It also provides significant guidance for screening high‐risk populations and developing intervention strategies.